2022
Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials
Krishnamurti L, Neuberg D, Sullivan K, Smith S, Eapen M, Walters M. Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials. Transplantation And Cellular Therapy 2022, 29: 217-221. PMID: 36270432, PMCID: PMC10539686, DOI: 10.1016/j.jtct.2022.10.008.Peer-Reviewed Original ResearchConceptsBone marrow transplantationSickle cell diseaseMarrow transplantationNonmalignant diseasesCell diseaseAdult sickle cell diseaseMyeloablative bone marrow transplantationSingle-arm feasibility studyYoung adultsCellular therapy trialsMulticenter National InstituteRegimen-related toxicitySingle-arm studyFrequency of HLACoronavirus disease 2019 (COVID-19) pandemicAcademic medical centerDisease 2019 pandemicShort-term endpointsBMT centersBMT regimenCare armPain episodesPrimary endpointStandard careCurative therapy
2019
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsPatient decision aidSickle cell diseaseWeb-based patient decision aidClinical trialsHealth care providersCell diseaseDecisional conflictPatient knowledgeCare providersDecision aid armStandard care armOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesBone marrow transplantationDecision aidCare armDecision aid prototypeClinical characteristicsBlood transfusionControlled TrialsPediatric patientsMarrow transplantationTherapeutic optionsCurative Therapies for Sickle Cell Disease.
Khemani K, Katoch D, Krishnamurti L. Curative Therapies for Sickle Cell Disease. Ochsner Journal 2019, 19: 131-137. PMID: 31258425, PMCID: PMC6584191, DOI: 10.31486/toj.18.0044.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseHaploidentical donorsSibling donorsCurative therapyUnrelated donorsCell diseaseHLA-identical sibling donorsRelated haploidentical donorsEvent-free survivalIdentical sibling donorsBone marrow transplantationStem cell transplantationAmelioration of symptomsHuman leukocyte antigenComparative clinical trialsGene therapyUse of HLAStable long-term engraftmentLong-term engraftmentMarrow transplantationRelated donorsSevere morbidityCurative treatmentOrgan damageBone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study
Krishnamurti L, Neuberg D, Sullivan K, Kamani N, Abraham A, Campigotto F, Zhang W, Dahdoul T, De Castro L, Parikh S, Bakshi N, Haight A, Hassell K, Loving R, Rosenthal J, Smith S, Smith W, Spearman M, Stevenson K, Wu C, Wiedl C, Waller E, Walters M. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal Of Hematology 2019, 94: 446-454. PMID: 30637784, PMCID: PMC6542639, DOI: 10.1002/ajh.25401.Peer-Reviewed Original ResearchConceptsSevere sickle cell diseaseBone marrow transplantationEvent-free survivalSickle cell diseaseMarrow transplantationCell diseaseElevated tricuspid regurgitant jet velocityRegular red blood cell transfusionsSevere SCDDonor bone marrow transplantationOne-year overall survivalSecond bone marrow transplantationTricuspid regurgitant jet velocityRed blood cell transfusionProspective multicenter pilot studyDeveloped chronic GVHDHost disease (GVHD) prophylaxisStable donor chimerismAcute chest syndromeSecondary graft failureBlood cell transfusionHealth-related qualityPhysical function domainProspective clinical trialsRegurgitant jet velocity
2017
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
Bakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease. PLOS ONE 2017, 12: e0178413. PMID: 28727801, PMCID: PMC5518995, DOI: 10.1371/journal.pone.0178413.Peer-Reviewed Original ResearchConceptsSickle cell diseaseChronic blood transfusionsBone marrow transplantationDisease-modifying therapiesTreatment-related decisionsTreatment optionsCell diseasePhysician perspectivesAvailable disease-modifying therapiesLong-term adverse effectsPhysician-related factorsAvailable treatment optionsDisease-related factorsPossible treatment optionsPatients/familiesInherited blood disorderBlood transfusionMarrow transplantationPhysician interviewsPatient burdenPhysicians' perceptionsPatient's perspectivePhysicians' approachPatient engagementTreatment plan
2016
Experiences and Decision Making for Bone Marrow Transplant in Sickle Cell Disease: Patients and Caregivers Perspective
Khemani K, Ross D, Haight A, Sinha C, Bakshi N, Krishnamurti L. Experiences and Decision Making for Bone Marrow Transplant in Sickle Cell Disease: Patients and Caregivers Perspective. Blood 2016, 128: 2393. DOI: 10.1182/blood.v128.22.2393.2393.Peer-Reviewed Original ResearchBone marrow transplantationBone marrow transplantSickle cell diseasePatient age rangeMarrow transplantTreatment optionsCell diseaseMost patientsTransplant processBMT processBMT teamAge rangeEffect of BMTClinical situationsFertility issuesOnly curative treatment optionChemotherapy-related side effectsTransplant-related complicationsCurative treatment optionTime of transplantPatient-caregiver dyadsMedian valuePatient's clinical situationTime of interviewRisk/benefitShared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell Disease
Bakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Shared Decision Making or Physician Advocate for a Particular Treatment Option: A Spectrum of Approaches to Decision Making about Disease Modifying Therapies in Sickle Cell Disease. Blood 2016, 128: 4757. DOI: 10.1182/blood.v128.22.4757.4757.Peer-Reviewed Original ResearchBone marrow transplantationSickle cell diseaseChronic blood transfusionsTherapeutic optionsTreatment optionsCurrent clinical conditionPhysician narrativesTherapeutic planCell diseasePatient valuesTreatment planAdult sickle cell diseaseDisease-modifying therapeutic optionsPatient’s current clinical conditionLong-term side effectsDecisional needsDisease-Modifying TherapiesMajority of patientsGroup of patientsPatient-related factorsAvailable treatment optionsGood clinical evidenceProgression of diseaseParticular treatment optionPatients' decision processesWhat Are the Expectations of Patients in Decision Making Process for Disease Modifying Therapies for Sickle Cell Disease: Do They Care about Shared Decision Making?
Ross D, Bakshi N, Khemani K, Sinha C, Loewenstein G, Krishnamurti L. What Are the Expectations of Patients in Decision Making Process for Disease Modifying Therapies for Sickle Cell Disease: Do They Care about Shared Decision Making? Blood 2016, 128: 5968. DOI: 10.1182/blood.v128.22.5968.5968.Peer-Reviewed Original ResearchSickle cell diseasePerspectives of patientsLong-term outcomesMedical historyExpectations of patientsCell diseaseDisease-Modifying TherapiesChronic blood transfusionsPast medical historyBone marrow transplantationGood clinical evidencePatient's medical historyImpact of treatmentPatients' personal valuesImportance of patientsInterview guideMedical decisionsHealth care decisionsModifying therapiesBlood transfusionMarrow transplantationClinical evidenceTreatment optionsOpen-ended interview guideComplex medical decisions
2008
Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects
Krishnamurti L, Gupta D. Hematopoietic stem cell transplantation for hemoglobinopathies: Progress and prospects. Indian Journal Of Medical And Paediatric Oncology 2008, 29: 39-48. DOI: 10.4103/0971-5851.51444.Peer-Reviewed Original ResearchSickle cell diseaseRisk factorsAllogeneic bone marrow transplantationClass IIHematopoietic stem cell transplantationClass ITransplant related morbidityUnrelated donor transplantsHLA-identical donorHLA-identical siblingsStem cell transplantationBone marrow transplantationCourse of diseaseLong-term survivalYears of ageAntithymocyte globulinAllogeneic SCTTransplant outcomesDonor transplantsRelated morbidityMarrow transplantationCell transplantationCell diseaseProbability of survivalTerm survival